Monoclonal antibodies targeting IL‐6 (Siltuximab) and the IL‐6 receptor (IL‐6R) (Tocilizumab) have emerged as promising immunotherapeutic agents, utilisable as standalone treatments or in conjunction with traditional chemotherapy, for tumour therapy.154, 158. Here, IL6 is linked to neoplasm.